-+ 0.00%
-+ 0.00%
-+ 0.00%

Cue Biopharma Q3 net loss widens to $50.02 million

PUBT·11/16/2026 21:48:53
Listen to the news
Cue Biopharma Q3 net loss widens to $50.02 million
  • Cue Biopharma’s third-quarter 2026 net loss widened to $50.02 million.
  • Revenue fell 94% year over year to $132,000 due to lower recognition under the BI collaboration agreement.
  • Research and development expenses more than tripled to $17.02 million, primarily due to clinical-development initiation costs and non-cash stock-based compensation.
  • Cash and cash equivalents totaled $57.94 million at September 30, 2026.
  • CUE-221 demonstrated statistically significant Phase 2 CSU benefits; first-in-human dosing began for autoimmune candidate CUE-401.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cue Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611161648PRIMZONEFULLFEED9878883) on November 16, 2026, and is solely responsible for the information contained therein.